Alzheimer’s doesn’t begin the day you notice memory loss. Dr. David Perlmutter explains that the changes leading to cognitive decline can be developing for decades before symptoms become obvious. That’s why your 30s and 40s matter. Metabolic health, movement, sleep, and the choices you make today can all play a role in your long-term brain health. We need to stop waiting for symptoms to start thinking about prevention.

Alzheimer’s doesn’t start when you forget someone’s name. It can begin decades earlier. Insulin resistance and high blood sugar are closely tied to cognitive decline, yet millions of people are walking around prediabetic and don’t even know it. Today's new episode with Dr. David Perlmutter is personal for me. I’m watching my own mother go through this, and I’m motivated on learning everything I can to help her while giving my kids the tools to protect their brain health decades before symptoms ever show up. We need to stop waiting for disease to show itself before we take action.

Alzheimer’s doesn’t start when you forget someone’s name... the biological changes can begin years before symptoms ever show up. Dr. David Perlmutter joins me to break down early detection, metabolic health, and the everyday factors that may shape long-term brain health. Watch the full episode right here on X...

Alzheimer’s is one of the most devastating diseases, killing ~2 million people globally each year and costing over $1 trillion annually. It also remains one of the hardest unsolved problems in medicine. We believe advanced AI can help change that:

World Alzheimer's Day takes place every Sept. 21 as a global effort to raise awareness & challenge stigma around Alzheimer's disease & other dementia. #WorldAlzheimersDay# #RichmondBC# #richmondfamilies# #dementiaawareness# #KinderCommunity# #riterichmond# #dickey4council#

What if Alzheimer’s isn’t as simple as memories just disappearing? In Alzheimer’s disease, changes in the brain, including amyloid plaques and neurofibrillary tangles, can disrupt the networks involved in forming and retrieving memories. That distinction matters because researchers are continuing to study why memory retrieval fails and what might help preserve cognitive function as the disease progresses. There’s still so much to understand about the brain and Alzheimer’s.

Mark World Alzheimer’s Month by exploring the latest advances in PET imaging using these free, regionally focused clinical simulations, designed to optimize your selection, interpretation, and reporting of PET biomarkers in practice:

Oligonucleotide drug slows Alzheimer’s decline across every dose tested in Phase 2 and reframes the field’s central therapeutic target. #longevity# #geroscience# #Alzheimers# #oligonucleotide# #Phase2#